Cyclo Therapeutics currently holds 198.78
K in liabilities. This firm has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
We provide trade advice to complement the prevailing
expert consensus on Cyclo Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Cyclo Therapeutics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cyclo Therapeutics based exclusively on its
fundamental and basic
technical indicators. By analyzing Cyclo Therapeutics's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Cyclo Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cyclo Therapeutics. We calculate exposure to Cyclo Therapeutics's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Cyclo Therapeutics's related companies.
Watch out for price decline
Please consider monitoring Cyclo Therapeutics on a daily basis if you are holding a position in it. Cyclo Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Cyclo Therapeutics stock to be traded above the $1 level to remain listed. If Cyclo Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Cyclo Therapeutics Investment Alerts
Cyclo investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Cyclo Therapeutics performance across your portfolios.Please check all
investment alerts for Cyclo
Cyclo Therapeutics Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Cyclo value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyclo Therapeutics competition to find
correlations between indicators driving the intrinsic value of Cyclo.
Cyclo Therapeutics Gross Profit
Cyclo Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Cyclo Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Cyclo Therapeutics Gross Profit growth over the last 10 years. Please check Cyclo Therapeutics'
gross profit and other
fundamental indicators for more details.
Detailed Perspective On Cyclo Therapeutics
The company reported the previous year's revenue of 985.15
K. Net Loss for the year was (8.9
M) with profit before overhead, payroll, taxes, and interest of 769.64
K.
| 2018 | 2019 | 2020 | 2021 (projected) |
Current Assets | 2.77 M | 3.96 M | 14.05 M | 15.16 M | Total Assets | 2.92 M | 4.11 M | 14.19 M | 15.31 M |
Margins Breakdown
Cyclo profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Cyclo Therapeutics itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Cyclo Therapeutics profit margins.
| EBITDA Margin | (10.14) |
| Gross Margin | 0.99 |
| Profit Margin | (10.16) |
Cyclo Therapeutics Earnings before Tax is nearly stable at the moment. Cyclo Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. The previous year's value of Cyclo Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA was -9,163,809. Furthermore, Cyclo Therapeutics Average Assets is increasing over the last 8 years. Cyclo Therapeutics Earnings before Tax is nearly stable at the moment. Cyclo Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. Furthermore, Cyclo Therapeutics Average Assets is increasing over the last 8 years. The current value of Cyclo Therapeutics Average Assets is 4,995,295.
Our perspective of the current Cyclo Therapeutics rise
Cyclo Therapeutics current market risk adjusted performance boosts over 1.31. Cyclo Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Cyclo Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Cyclo Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cyclo Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cyclo Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
While some other firms under the biotechnology industry are still a bit expensive, Cyclo Therapeutics may offer a potential longer-term growth to stockholders. To conclude, as of the 1st of May 2021, we see that Cyclo Therapeutics follows the market closely. The company is
undervalued with
low odds of financial distress within the next 24 months. However, our ongoing 30 days buy vs. sell advice on the company is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Cyclo Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
